InMed Pharmaceuticals (INM) Depreciation & Amortization - Total (2019 - 2025)

InMed Pharmaceuticals has reported Depreciation & Amortization - Total for 6 years, with the latest figure at $12206.0 in Q2 2025.

• On a quarterly basis, Depreciation & Amortization - Total rose 124.37% year-over-year to $12206.0 in Q2 2025; TTM through Jun 2025 was $50204.0, a 5.16% increase from a year earlier, with the FY2025 full-year figure at $50204.0, up 5.16% from the prior year.
• Depreciation & Amortization - Total was $12206.0 for Q2 2025 at InMed Pharmaceuticals, roughly flat from $12203.0 in the prior quarter.
• The five-year high for Depreciation & Amortization - Total was $14242.0 in Q4 2023, with the low at $5440.0 in Q2 2024.
• Average Depreciation & Amortization - Total over 4 years is $11773.0, with a median of $12209.0 recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization - Total tumbled 57.88% in 2024, then jumped 124.37% in 2025.
• Over 4 years, Depreciation & Amortization - Total stood at $8056.0 in 2022, then soared by 76.79% to $14242.0 in 2023, then slipped by 14.27% to $12209.0 in 2024, then fell by 0.02% to $12206.0 in 2025.
• The last three Depreciation & Amortization - Total figures came in at $12206.0 (Q2 2025), $12203.0 (Q1 2025), and $12209.0 (Q4 2024), per Business Quant data.